EVERETT HISTORICAL / SHUTTERSTOCK.COM
Nearly three years after the introduction of the inter partes review, LSIPR explores its impact on the life sciences sector and asks whether it is creating a culture of ‘reverse trolling’.
Sometimes, a good tool can find itself in the wrong hands.
In September 2012, the America Invents Act (AIA) introduced the inter partes review (IPR), a quicker, more cost-effective way of challenging patents on the basis of prior art consisting of patents or printed publications.
The AIA patent reform was squarely aimed at curbing the activities of non-practising entities (NPEs), also known as ‘patent trolls’, which had made life unpredictable for innovators in the tech industry.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
inter-partes review, AIA, NPEs, IPR, US Court of Appeals for the Federal Circuit, patent troll,